{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T11:54:46Z","timestamp":1768478086796,"version":"3.49.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1016\/j.ejpb.2013.05.018","type":"journal-article","created":{"date-parts":[[2013,6,11]],"date-time":"2013-06-11T13:50:07Z","timestamp":1370958607000},"page":"1293-1299","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"special_numbering":"PB","title":["The interaction of nifedipine with selected cyclodextrins and the subsequent solubility\u2013permeability trade-off"],"prefix":"10.1016","volume":"85","author":[{"given":"Avital","family":"Beig","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan M.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arik","family":"Dahan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2013.05.018_b0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2008.03.021","article-title":"Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs","volume":"129","author":"Dahan","year":"2008","journal-title":"Journal of Controlled Release"},{"key":"10.1016\/j.ejpb.2013.05.018_b0010","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1021\/mp100157s","article-title":"A pH-dilution method for estimation of biorelevant drug solubility along the gastrointestinal tract: application to physiologically based pharmacokinetic modeling","volume":"7","author":"Gao","year":"2010","journal-title":"Molecular Pharmaceutics"},{"key":"10.1016\/j.ejpb.2013.05.018_b0015","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Advanced Drug Delivery Reviews"},{"key":"10.1016\/j.ejpb.2013.05.018_b0020","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1517\/17425240903222218","article-title":"Recent advances and future directions in amphiphilic cyclodextrin nanoparticles","volume":"6","author":"Bilensoy","year":"2009","journal-title":"Expert Opinion on Drug Delivery"},{"key":"10.1016\/j.ejpb.2013.05.018_b0025","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.addr.2007.05.012","article-title":"Cyclodextrins as pharmaceutical solubilizers","volume":"59","author":"Brewster","year":"2007","journal-title":"Advanced Drug Delivery Reviews"},{"key":"10.1016\/j.ejpb.2013.05.018_b0030","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ejpb.2009.04.013","article-title":"Comparative evaluation of polymeric and amphiphilic cyclodextrin nanoparticles for effective camptothecin delivery","volume":"73","author":"Cirpanli","year":"2009","journal-title":"European Journal of Pharmaceutics and Biopharmaceutics"},{"key":"10.1016\/j.ejpb.2013.05.018_b0035","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/nrd1576","article-title":"Cyclodextrin-based pharmaceutics: past, present and future","volume":"3","author":"Davis","year":"2004","journal-title":"Nature Reviews Drug Discovery"},{"key":"10.1016\/j.ejpb.2013.05.018_b0040","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1021\/js950534b","article-title":"Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization","volume":"85","author":"Loftsson","year":"1996","journal-title":"Journal of Pharmaceutical Sciences"},{"key":"10.1016\/j.ejpb.2013.05.018_b0045","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1021\/js960075u","article-title":"Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery","volume":"85","author":"Rajewski","year":"1996","journal-title":"Journal of Pharmaceutical Sciences"},{"key":"10.1016\/j.ejpb.2013.05.018_b0050","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1208\/s12249-011-9612-3","article-title":"Complexation and full characterization of the tretinoin and dimethyl-\u03b2eta-cyclodextrin complex","volume":"12","author":"Ascenso","year":"2011","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ejpb.2013.05.018_b0055","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0378-5173(97)00104-X","article-title":"Inclusion complexes of tretinoin with cyclodextrins","volume":"153","author":"Montassier","year":"1997","journal-title":"International Journal of Pharmaceutics"},{"key":"10.1016\/j.ejpb.2013.05.018_b0060","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jconrel.2007.07.018","article-title":"The utility of cyclodextrins for enhancing oral bioavailability","volume":"123","author":"Carrier","year":"2007","journal-title":"Journal of Controlled Release"},{"key":"10.1016\/j.ejpb.2013.05.018_b0065","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1002\/jps.22033","article-title":"The solubility\u2013permeability interplay in using cyclodextrins as pharmaceutical solubilizers: mechanistic modeling and application to progesterone","volume":"99","author":"Dahan","year":"2010","journal-title":"Journal of Pharmaceutical Sciences"},{"key":"10.1016\/j.ejpb.2013.05.018_b0070","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1517\/17425247.2.1.335","article-title":"Cyclodextrins in drug delivery","volume":"2","author":"Loftsson","year":"2005","journal-title":"Expert Opinion on Drug Delivery"},{"key":"10.1016\/j.ejpb.2013.05.018_b0075","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1002\/jps.20992","article-title":"Effects of cyclodextrins on drug delivery through biological membranes","volume":"96","author":"Loftsson","year":"2007","journal-title":"Journal of Pharmaceutical Sciences"},{"key":"10.1016\/j.ejpb.2013.05.018_b0080","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.ijpharm.2012.03.017","article-title":"Predicting the solubility\u2013permeability interplay when using cyclodextrins in solubility-enabling formulations: model validation","volume":"430","author":"Miller","year":"2012","journal-title":"International Journal of Pharmaceutics"},{"key":"10.1016\/j.ejpb.2013.05.018_b0085","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1002\/jps.23093","article-title":"Perspective on improving passive human intestinal absorption","volume":"101","author":"Yalkowsky","year":"2012","journal-title":"Journal of Pharmaceutical Sciences"},{"key":"10.1016\/j.ejpb.2013.05.018_b0090","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.ejpb.2012.02.012","article-title":"Accounting for the solubility\u2013permeability interplay in oral formulation development for poor water solubility drugs: the effect of PEG-400 on carbamazepine absorption","volume":"81","author":"Beig","year":"2012","journal-title":"European Journal of Pharmaceutics and Biopharmaceutics"},{"key":"10.1016\/j.ejpb.2013.05.018_b0095","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1208\/s12248-012-9337-6","article-title":"The solubility\u2013permeability interplay and its implications in formulation design and development for poorly soluble drugs","volume":"14","author":"Dahan","year":"2012","journal-title":"The AAPS Journal"},{"key":"10.1016\/j.ejpb.2013.05.018_b0100","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1021\/mp200460u","article-title":"The solubility\u2013permeability interplay when using cosolvents for solubilization: revising the way we use solubility-enabling formulations","volume":"9","author":"Miller","year":"2012","journal-title":"Molecular Pharmaceutics"},{"key":"10.1016\/j.ejpb.2013.05.018_b0105","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1021\/mp200181v","article-title":"The solubility\u2013permeability interplay: mechanistic modeling and predictive application of the impact of micellar solubilization on intestinal permeation","volume":"8","author":"Miller","year":"2011","journal-title":"Molecular Pharmaceutics"},{"key":"10.1016\/j.ejpb.2013.05.018_b0110","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2165\/00137696-200402040-00006","article-title":"Role of cyclodextrins in improving oral drug delivery","volume":"2","author":"Loftsson","year":"2004","journal-title":"American Journal of Drug Delivery"},{"key":"10.1016\/j.ejpb.2013.05.018_b0115","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/jps.10341","article-title":"When can cyclodextrins be considered for solubilization purposes?","volume":"92","author":"Rao","year":"2003","journal-title":"Journal of Pharmaceutical Sciences"},{"key":"10.1016\/j.ejpb.2013.05.018_b0120","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1002\/jps.20831","article-title":"Practical considerations in development of solid dosage forms that contain cyclodextrin","volume":"96","author":"Miller","year":"2007","journal-title":"Journal of Pharmaceutical Sciences"},{"key":"10.1016\/j.ejpb.2013.05.018_b0125","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s10439-010-0169-1","article-title":"Drug salts and solubilization: modeling the influence of cyclodextrins on oral absorption","volume":"39","author":"Gamsiz","year":"2011","journal-title":"Annals of Biomedical Engineering"},{"key":"10.1016\/j.ejpb.2013.05.018_b0130","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/bit.22523","article-title":"Modeling the influence of cyclodextrins on oral absorption of low-solubility drugs: I. Model development","volume":"105","author":"Gamsiz","year":"2010","journal-title":"Biotechnology and Bioengineering"},{"key":"10.1016\/j.ejpb.2013.05.018_b0135","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/bit.22524","article-title":"Modeling the influence of cyclodextrins on oral absorption of low solubility drugs: II. Experimental validation","volume":"105","author":"Gamsiz","year":"2010","journal-title":"Biotechnology and Bioengineering"},{"key":"10.1016\/j.ejpb.2013.05.018_b0140","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1002\/jps.2600591112","article-title":"Binding specificity between small organic solutes in aqueous solution: classification of some solutes into two groups according to binding tendencies","volume":"59","author":"Higuchi","year":"1970","journal-title":"Journal of Pharmaceutical Sciences"},{"key":"10.1016\/j.ejpb.2013.05.018_b0145","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1021\/mp1001119","article-title":"Aqueous boundary layers related to oral absorption of a drug: from dissolution of a drug to carrier mediated transport and intestinal wall metabolism","volume":"7","author":"Sugano","year":"2010","journal-title":"Molecular Pharmaceutics"},{"key":"10.1016\/j.ejpb.2013.05.018_b0150","first-page":"117","article-title":"Phase-solubility techniques","volume":"4","author":"Higuchi","year":"1965","journal-title":"Advances in Analytical Chemistry and Instrumentation"},{"key":"10.1016\/j.ejpb.2013.05.018_b0155","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1021\/jm001020e","article-title":"High-throughput permeability pH profile and high-throughput alkane\/water logP with artificial membranes","volume":"44","author":"Wohnsland","year":"2001","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.ejpb.2013.05.018_b0160","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1021\/mp100175a","article-title":"High-permeability criterion for BCS classification: segmental\/pH dependent Permeability considerations","volume":"7","author":"Dahan","year":"2010","journal-title":"Molecular Pharmaceutics"},{"key":"10.1016\/j.ejpb.2013.05.018_b0165","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jconrel.2009.02.018","article-title":"Quasi-equilibrium analysis of the ion-pair mediated membrane transport of low-permeability drugs","volume":"137","author":"Miller","year":"2009","journal-title":"Journal of Controlled Release"},{"key":"10.1016\/j.ejpb.2013.05.018_b0170","first-page":"85","article-title":"Physical chemical analysis of percutaneous absorption process from creams and ointments","volume":"11","author":"Higuchi","year":"1960","journal-title":"Journal of the Society of Cosmetic Chemists"},{"key":"10.1016\/j.ejpb.2013.05.018_b0175","doi-asserted-by":"crossref","first-page":"146","DOI":"10.2174\/157016311795563884","article-title":"Modeling the effect of selected cyclodextrins on nifedipine solubility","volume":"8","author":"Agatonovic-Kustrin","year":"2011","journal-title":"Current Drug Discovery Technologies"},{"key":"10.1016\/j.ejpb.2013.05.018_b0180","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/jps.21396","article-title":"High-throughput phase-distribution method to determine drug\u2013cyclodextrin binding constants","volume":"98","author":"Chen","year":"2009","journal-title":"Journal of Pharmaceutical Sciences"},{"key":"10.1016\/j.ejpb.2013.05.018_b0185","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/BF01041558","article-title":"Phase solubility analysis in studying the interaction of nifedipine with selected cyclodextrins in aqueous solution","volume":"25","author":"Worthington","year":"1996","journal-title":"Journal of Inclusion Phenomena and Molecular Recognition in Chemistry"},{"key":"10.1016\/j.ejpb.2013.05.018_b0190","series-title":"Stoichiometry and Research \u2013 The Importance of Quantity in Biomedicine","first-page":"47","article-title":"The determination of the stoichiometry of cyclodextrin inclusion complexes by spectral methods: possibilities and limitations","author":"Tablet","year":"2012"},{"key":"10.1016\/j.ejpb.2013.05.018_b0195","doi-asserted-by":"crossref","first-page":"10456","DOI":"10.1021\/jp2053629","article-title":"Study of \u03b3-cyclodextrin host\u2013guest complex and nanotube aggregate by fluorescence correlation spectroscopy","volume":"115","author":"Mandal","year":"2011","journal-title":"The Journal of Physical Chemistry B"},{"key":"10.1016\/j.ejpb.2013.05.018_b0200","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.saa.2007.10.021","article-title":"Spectroscopic investigations and crystal structure from synchrotron powder data of the inclusion complex of \u03b2-cyclodextrin with atenolol","volume":"70","author":"Borodi","year":"2008","journal-title":"Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy"},{"key":"10.1016\/j.ejpb.2013.05.018_b0205","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s10847-009-9538-5","article-title":"Raman spectroscopy is a convenient technique for the efficient evaluation of cyclodextrin inclusion molecular complexes of azo-dye colorants and largely polarisable guest molecules","volume":"64","author":"Arrais","year":"2009","journal-title":"Journal of Inclusion Phenomena"},{"key":"10.1016\/j.ejpb.2013.05.018_b0210","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1023\/A:1008186706573","article-title":"Violacein\/\u03b2-cyclodextrin inclusion complex formation studied by measurements of diffusion coefficient and circular dichroism","volume":"37","author":"De Azevedo","year":"2000","journal-title":"Journal of Inclusion Phenomena"},{"key":"10.1016\/j.ejpb.2013.05.018_b0215","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10847-012-0191-z","article-title":"Inclusion of \u03b1-lipoic acid in \u03b2-cyclodextrin. Physical\u2013chemical and structural characterization","volume":"76","author":"Racz","year":"2013","journal-title":"Journal of Inclusion Phenomena"},{"key":"10.1016\/j.ejpb.2013.05.018_b0220","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/jps.1025","article-title":"Comparative studies of the enhancing effects of cyclodextrins on the solubility and oral bioavailability of tacrolimus in rats","volume":"90","author":"Arima","year":"2001","journal-title":"Journal of Pharmaceutical Sciences"},{"key":"10.1016\/j.ejpb.2013.05.018_b0225","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.ejpb.2008.06.024","article-title":"Inclusion complexes of tadalafil with natural and chemically modified \u03b2-cyclodextrins. I: Preparation and in-vitro evaluation","volume":"70","author":"Badr-Eldin","year":"2008","journal-title":"European Journal of Pharmaceutics and Biopharmaceutics"},{"key":"10.1016\/j.ejpb.2013.05.018_b0230","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1007\/s11095-006-9054-x","article-title":"Use of a dynamic in vitro lipolysis model to rationalize oral formulation development for poor water soluble drugs: correlation with in vivo data and the relationship to intra-enterocyte processes in rats","volume":"23","author":"Dahan","year":"2006","journal-title":"Pharmaceutical Research"},{"key":"10.1016\/j.ejpb.2013.05.018_b0245","doi-asserted-by":"crossref","unstructured":"A. Beig, R. Agbaria, A. Dahan. Oral delivery of lipophilic drugs: The tradeoff between solubility increase and permeability decrease when using cyclodextrin-based formulations. Plos One (2013) in press.","DOI":"10.1371\/annotation\/10ae05dc-90cb-46f1-aa2b-e63eb4a132e2"}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641113002178?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641113002178?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,15]],"date-time":"2018-10-15T06:57:11Z","timestamp":1539586631000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641113002178"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S0939641113002178"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2013.05.018","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The interaction of nifedipine with selected cyclodextrins and the subsequent solubility\u2013permeability trade-off","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2013.05.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}